It is plausible that combination therapy achieving ADAM10 inhibition and antiplatelet activity may be particularly effective in the management of sepsis caused by those pathogens that elicit complex microvascular injury through an ADAM10-dependent mechanism. This evidence concerns the gene ADAM10 and Sepsis.